Skip to Content

Trilaciclib Disease Interactions

There are 3 disease interactions with trilaciclib:


Trilaciclib (Includes trilaciclib) liver dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Liver Disease

The use of trilaciclib is not recommended in patients with moderate or severe liver dysfunction as its pharmacokinetics have not been studied in these patients. No dosage adjustment is recommended for patients with mild liver dysfunction.


Trilaciclib (Includes trilaciclib) pulmonary dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Pulmonary Impairment

The administration of cyclin-dependent kinases 4/6 inhibitors such as trilaciclib can cause severe, life-threatening, or fatal interstitial lung disease (ILD) and/or pneumonitis. It is recommended to exercise caution when using this agent in patients with a history of ILD and/or pneumonitis. Monitor for pulmonary symptoms indicative of ILD/pneumonitis. Interrupt and evaluate patients with new or worsening symptoms suspected to be due to ILD/pneumonitis. Permanently discontinue treatment in patients with recurrent symptomatic or severe/life-threatening ILD/pneumonitis.


Trilaciclib (Includes trilaciclib) renal dysfunction

Moderate Potential Hazard, Moderate plausibility. Applies to: Renal Dysfunction

No clinically significant differences in the pharmacokinetics of trilaciclib were observed in patients with mild to moderate renal dysfunction. The effect on the pharmacokinetics in patients with severe renal dysfunction, end-stage renal dysfunction, or dialysis has not been studied. Care should be exercised when using this agent in these patients.

Trilaciclib drug interactions

There are 9 drug interactions with trilaciclib

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.